Zydus Cadila receives USFDA nod for Cisatracurium Besylate Injection

Zydus Cadila informed the bourses on Wednesday that it has received final approval from United States Food & Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP in the strength of 20 mg (base)/10 ml (2 mg/ml) multiple-dose vial. The drug will be manufactured at Liva plant of Cadila Healthcare Limited.

The said drug is a nondepolarising skeletal neuromuscular blocker for intravenous administration. It is a supplement to general anaesthesia to facilitate tracheal intubation in adults and in paediatric patients of 1 month to 12 years of age. It also provides skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the intensive care unit (ICU).

Zydus Cadila is a pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group now has 297 approvals and has so far, filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

At 12 pm on Wednesday, the stock of Cadila Healthcare was trading at Rs 374.60 per share, lower by 0.94 per cent or Rs 3.55 per share on BSE, against a 0.15 per cent decline in the benchmark index. The 52-week high is recorded at Rs 411.60 and the 52-week low is Rs 212.70 on BSE.